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Sternal wound infections (SWI) continue to be a major cause of concern after cardiac surgery. It leads to prolonged
hospital stay and increased morbidity, mortality and increased hospital costs. Prophylactic systemic antibiotics have
been used to prevent surgical site infection (SSI). However, prolonged postoperative use of systemic antibiotics can
lead to emergence of resistant organisms. Gentamycin Containing Collagen Implants (GCCI) when used during
sternotomy closure produces high local antibiotic concentrations in the wound with a low serum concentration.
There is evidence that the concentration of gentamicin in the mediastinal fluid reaches levels high enough to be
effective against bacteria that are considered resistant to gentamycin and other antibiotics.
However, questions have been raised about the safety and efficacy of GCCI. There were concerns whether GCCI can
lead to systemic absorption with renal impairment and whether use of topical antibiotics can lead to emergence of
antimicrobial resistance.
We, hereby, review the literature on GCCI (Collatamp) and take the opportunity to appraise the scientific
community about their role in cardiac surgery. Several recent studies have supported their clinical effectiveness.
They should be used in dry condition and should not be soaked in saline even for a short period prior to use.
However, for GCCI to become part of routine practice in cardiac surgery further large randomised studies are
required. As the incidence of sternal wound infection is low in the specialty of cardiac surgery, for any study to be
sufficiently powered to address this issue, multicenter studies might be the way forward.
Based on the evidence presented in this manuscript it is recommended GCCI (Collatamp) can be a cost effective adjunct
for prevention of sternal wound infection. They can also be used for treatment of Deep Sternal Wound Infection.
Keywords: Surgical site infection, Supercial sternal wound infection, Deep sternal wound infection, Mediastinitis, Topical
gentamicin, Gentamycin containing collagen implants, CollatampReview
Surgical Site Infections (SSI) is associated with increased
length of hospital stay and cost of care [1]. Sternal
wound infection (SWI) after cardiac surgery continues to
be one of the most serious postoperative complications
[2-6]. Superficial Sternal Wound infection (SSWI) leads to
increased morbidity while Deep Sternal Wound Infection
(DSWI) after cardiac surgery is a serious complication
causing substantial increase in both morbidity and
mortality. Efforts have been made to decrease the
incidence to SWI. However, despite all efforts, DSWI* Correspondence: mishrapk_25@yahoo.com
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unless otherwise stated.is an everyday challenge in the life of a cardiothoracic
surgeon.
In the last decade, new ways have been investigated
to reduce the incidence of SSWI and DSWI. After
positive experience in other specialties (e.g. colorectal
surgery, orthopaedics) with topical antibiotic preparations,
resorbable gentamicin-containing collagen implant (GCCI)
has been introduced in cardiac surgery in an effort to
reduce the incidence of sternal wound complications [7-9].
Gentamicin Containing Collagen Implant (GCCI) delivers
high local concentrations of gentamicin with low serum
levels [2-4]. The high local antibiotic concentrations may
have an effect on bacteria that are normally considered to
be resistant [2,10]. Although gentamicin is generally used
for gram-negative infections, it does have a spectrum ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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including staphylococci [11].
Gentamicin Containing Collagen Implant (GCCI) are
licensed for use in cardiac surgery in over 50 countries
but their effectiveness at preventing sternal wound
infections (SWIs) continues to be debated [1,2,12].
We hereby, review the published clinical data for
prophylactic application of resorbable GCCI following
cardiac surgery. We take the opportunity to appraise
the scientific community about the safety and efficacy
of GCCI in prevention of postoperative sternal wound
complication.Definition and classification of SSI
The criteria for definition and classification of Surgical
Site Infections (SSI) in the literature vary. A majority of
studies have used criteria laid down by Centers of
Disease Control and prevention for surgical site infection
[2,13,14]. It is focused on the depth, but not on the clinical
severity, of the infection [13]. In UK NICE (National
Institute of Clinical Excellence) has issued guidelines
for recognition and management of SSI [15]. Deep SWI
includes all SWI with sternal dehiscence or infections
down to the sternum, even when the sternum remained
stable [2,13]. Infections are usually classified as definite if
both clinical signs of infection and prespecified bacterial
cultures were positive [1,2,13]. A more comprehensive
clinical wound scoring system, such as the ASEPSIS score
will be more informative but more laborious to use [16,17].Pathophysiology of Sternal Wound Infection (SWI)
Incidence and Risk factors
The reported incidence of postoperative SWI varies
considerably; because of differences in definitions and
classification of infections and variations in follow-up
[2,18-27]. Sternal wound infection (SWI) has a reported
overall incidence between 0.5% and 6% [1]. However, in
high-risk patients the incidence has been estimated at
between 12 and 20% with an associated mortality rate
between 14% and 47% [7,18-22]. Schersten et al. suggest
that the incidence of SSI goes higher in studies reporting
surgery on high-risk patients and also in patients
undergoing emergency operations [28].
Sternal wound infections can be divided into superficial
and deep infections (DSWI) [23]. Sternal infections can also
be classified as early and late [23,26]. Late infections include
osteomyelitis, subcutaneous abscess, sterno-cutaneous
fistulas and mediastinitis [23]. In cardiac surgery, numerous
risk factors for SSI exist, such as obesity, diabetes, COPD,
re-operation, use of two internal mammary arteries, and
duration of surgery [7,25,29-32]. In the presence of bacterial
contamination a slight instability in an osteal fixation
promotes the development of clinical infection [33,34].Bacteriology
The most common bacteria involved in postoperative
wound infections are Gram-positive cocci, mainly
staphylococci— either coagulase-negative staphylococci
(CoNS) or Staphylococcus aureus [35-37].
Coagulase-negative staphylococci (CoNS) (usually S.
epidermidis) have become the most common cause of
SWI in many of the reported series [33]. CoNS were
also the most commonly present agent in cases with
multiple bacterial agents [33-35]. 80% were resistant
to aminoglycosides and 81% were resistant to methicillin
[33]. CoNS often cause chronic infections by forming a
biofilm through attachment to an implanted device such
as steel wires following median sternotomy [38]. Other
organisms e.g. Streptococci, Gram-negative bacteria
and fungi, especially Candida albicans, can also cause
SWI [39,40].
Prevention of DSWI
Techniques to decrease SSI include preoperative skin
care, aseptic surgical technique, gentle tissue handling
and perioperative antibiotic cover [41-43]. Intravenous
(IV) antibiotic prophylaxis for median sternotomy has
been clearly shown to reduce the wound infection rate
in several studies and is a routine practice in most
cardiothoracic units [27]. There is some evidence that
rigid sternal fixation with, usage of seven or more single
sternal fixation wires leads to a lower rate of SWI,
compared with only six single wires [33,44].
Topical antibiotics and GCCI
Gentamicin is predominantly used for gram-negative
infections. However, it does have a spectrum of bactericidal
activity for many gram-positive organisms, including
staphylococci [2,45-48]. Administration of systemic antibi-
otics may lead to a greater risk of antibiotic resistance
[46-48]. The emergence of local antibiotic-eluting products
such as resorbable gentamicin-containing collagen implant
(GCCI) enables delivery of high local concentrations of
gentamicin with corresponding low serum levels. The use
of collagen as a carrier also has a positive effect on wound
healing [33].
GCCI sponges were introduced in 1985 for the preven-
tion of surgical site infection and they were mainly used
after laparotomy [49]. GCCI can be an effective adjunct
in reducing the rate of SSI following cardiac surgery
particularly in high risk patients [50]. GCCI may also have
a role to play in the treatment of established DSWI [51].
However, currently there is no consensus about their use
in patients undergoing cardiac surgery [49].
Collatamp
Collatamp® (Collatamp® G EUSA Pharma Europe) is a
lyophilised collagen delivery system for gentamicin, used
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collagen is rapidly absorbed and is an efficient vehicle
for local antibiotics delivery. The implants are degraded
by collagenases, and do not need to be surgically removed
[53]. Collatamp® delivers a high dose of gentamicin, the
level and speed of which is dependent on the local blood
flow at the site of the wound [54]. The antibiotic is
concentrated locally in the tissue and does not reach
significant serum levels, which reduces the risk of systemic
side effects (ototoxicity/nephrotoxicity) [54]. Collatamp®
also accelerates haemostasis and positively influences
wound healing [53,54]. There is evidence that the
concentration of gentamicin in the mediastinal fluid
reaches levels high enough to be effective against bacteria
that are normally considered resistant (including most
CoNS) [2,10,51].
Mechanism of action and pharmacokinetics
Synthetic collagen-based products have been used for
their angiogenic properties and their role as a matrix or
“scaffold” to promote fibroblast migration and granulation
tissue formation [55-59]. Collatamp helps local haemostasis
and has been advocated for use in areas with seeping
haemorrhage with a high risk of infection. Haemostasis is
triggered when blood comes into contact with exposed
endogenous collagen fibrils or renatured collagen fibrils
like those in Collatamp. The adhesion and aggregation of
platelets is induced on the collagen fibrils of Collatamp
and the coagulation process is accelerated. The sponge-like
structure of Collatamp stabilises the wound clot and also
promotes granulation and epithelialisation. Overall effect is
accelerated granulation tissue formation and enhanced
healing process [51,60,61].
Systemically administered, gentamicin may be toxic
[7,62]. However, locally administered, the serum concen-
trations remain well below toxic levels [7,53,62]. The
pathogens involved in SSIs after cardiac surgery is mainly
coagulase-negative staphylococci (Staph Epidermidis)
and Staph aureus, especially in deep infections [4,7,29].
Gentamicin has good activity on these organisms [7,53].
The bactericidal effect of aminoglycosides is dependent
on the peak level, and a high peak level is associated with
a high bactericidal effect [51,63,64]. The minimum
inhibitory concentration (MIC) of gentamicin for systemic
antibiotic therapy is 4 mg/L. Leyh et al. showed that with
GCCI high local gentamicin levels (>300 mg/L) for 36 h
are detected in mediastinal effusions [50]. Serum con-
centrations remain low (1–4 mg/L 1 h postoperatively
and ≥1.5 mg/L after 24 h). These values are well below the
toxic threshold (10 mg/L) [51,53].
Therefore, a high bactericidal concentration of gentamicin
in the anterior mediastinum and sternal bone can be
anticipated. Besides, resistance is not an absolute feature
of bacteria, but it results from the relation of growthinhibitory concentration of the bacteria to inhibitory
concentration in the tissue. Grimm et al. demonstrated
that bacteria which are resistant at the minimal inhibitory
concentration (MIC) level are sensitive to higher gentamicin
levels [65]. The peak local levels of gentamicin with GCCI
are 75–200 times higher than the MIC making it highly
effective against even resistant isolates [51]. In the study of
Leyh et al., high bactericidal gentamicin levels were detected
for 36 h after surgery [51]. It is uncertain how long
gentamicin remains in mediastinal tissues, but release
is dependent on the local blood flow [51].
Gentamicin kills bacteria by inhibiting protein synthesis
and destabilizes bilayered membranes of bacteria [7].
Thus, each component of collagenous gentamycin may be
effective, whereby gentamicin acts as a bactericidal agent
and the carrier substance collagen possibly supports the
wound healing process and bone regeneration [7,51].
Initially concerns were raised that introduction of a
topical antibiotic prophylaxis could induce antibiotic
resistance with subsequent reduced effect of the prophy-
laxis [33]. However, pharmacokinetics of topical use of
Collatamp shows an early high peak in the local gentamicin
concentration, low serum concentrations and then rapid
disappearance of the drug which reduces the selection of
resistant bacteria. This pharmacokinetic profile is even
favourable compared to normal IV use [2,10].
Use of collatamp in cardiac surgery
Collatamp is available in 3 different presentations:
5 cm × 5 cm; 10 cm × 10 cm and 5 cm × 20 cm sizes
[66]. Collatamp® implants are wrapped around the
sternal edges prior to wound closure to ensure maximal
concentration of gentamicin on all sides of the wound and
inside the bone marrow. Sternal wires are used along the
length of the sternum to firmly close the wound. Though
collagen is rapidly resorbed, earlier it was argued that
placing the collagen sponges between the sternal halves,
rather than behind the sternum, might affect the sternal
healing. Friberg et al. did not identify any such adverse
effect [2,10,33,44]. However, the authors have emphasised
the importance of a rigid fixation (defined as at least seven
single sternal fixation wires), with complete compression
of the sponges], to achieve a maximal reduction in deep
infections by the collagen-gentamicin implant [44]. Too
thick layer of Collatamp should be avoided as it can
promote sternal instability [28].
Collatamp strips can also be used in vein harvesting
site closure. Collatamp can be cut to size to fit the area to
be treated. For SVG (Saphenous Vein Graft) harvesting
site, once the vein has been removed, one 5 × 20 cm
Collatamp® implant can be folded and packed into the
open wound. The wound is then closed with sutures.
However, the patient’s body weight and the total
amount of gentamicin should be taken into account.
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closure the number and size of the implants should be
selected so that a total dose of 9 mg gentamicin sulphate
per kg body weight is not exceeded [66]. Collatamp®
should be stored between 4°C and 25°C [66].
Cautions and contraindications
Collatamp® is approved for commercial use within the
European Union. No evidence of allergic reactions or ad-
verse local effects on sternal healing has been reported
[2]. In one study a higher incidence of early reoperation
for bleeding in the Collatamp group was reported [2].
No side effects have been reported to date [2,43,50,51]. If
the recommended maximum dose is exceeded, gentamicin-
specific side effects cannot be ruled out completely,
especially in the case of renal failure [66].
Systemically effective therapeutic blood or plasma levels
are not generally achieved with the use of Collatamp®.
However, interactions related to gentamicin should be
considered. Besides, in patients with impaired renal
function, the benefits of Collatamp® must be carefully
considered [2,10,12,66].
Collatamp should not be used if a protein allergy is
known or intolerability towards gentamicin has been
observed. No experience has been gained in use during
pregnancy and breast-feeding [66]. For this reason, the
indication should be strictly established during pregnancy
and breast-feeding [66].
No interactions have been reported to date. If adjuvant
systemic treatment with gentamicin, other aminoglycoside
antibiotics or other ototoxic or nephrotoxic drugs is
necessary, the cumulative effects should be taken into
account. In general, the number and size of the sponges
should be selected so that a total dose of 9 mg gentamicin
sulphate per kg body weight is not exceeded [66].
Cost analysis
DSWI are the most common cause of prolonged
hospital stay and increased hospital costs [7,19-22,50,51].
For GCCI to become part of routine practice clinical
effectiveness has to be matched with cost effectiveness
[12]. The use of Collatamp as an adjunct to IV antibiotics
was found to be cost saving step [2,44]. This was due to
fewer wound infections and lower costs involved in
subsequent treatment despite the cost of the implants
[2,44]. This was particularly relevant for high-risk patients
e.g. those with diabetes or BMI > 25 kg/m2 [44]. CoNS
infections have an insidious presentation. They are
difficult to treat, requiring prolonged courses of antibiotics,
often requiring extensive surgical debridement with the
use of muscle flaps [2,67]. It results in consumption
of substantial healthcare resources [2,67].
Eklund et al. suggests that it would be economical to
use gentamicin-collagen implants in every CABG patient,since the treatment of mediastinitis is extremely expensive
[7,50,51]. Friberg et al. concluded that despite the high
cost of the gentamicin impregnated sponges, the use
of two sponges, in addition to intravenous antibiotic
prophylaxis, was cost effective, resulting in both lower
costs and fewer infections for all patients as well as
for high risk patients [2,44].
Clinical effectiveness: literature review
A wealth of literature is now available on GCCI and
Collatamp®. Friberg et al. (Table 1) published a large
double blind RCT (LOGIP Trial) on the role of GCCI in
cardiac surgery [2]. Sternal closure was performed by
the senior members of the team i.e. the operating
surgeon. This study demonstrated an overall relative risk
reduction in SSI in the GCCI-treated patients compared
to the control group. The GCCI group demonstrated
reduced need for surgical revision (2.3% vs. 4.0%) and
postoperative IV antibiotic usage (11.6% vs. 18.0%) [2].
Use of GCCI was shown to be even more beneficial in
preventing both SSWI and DSWI in high-risk patients.
In obese patients the difference in DSWI did not
attend statistical significance. No significant difference
in postoperative renal function or 60 day mortality was
found. There was also no indication of any increase in
the occurrence of gentamicin-resistant isolates. An
unexplained finding was the significantly higher rebleeding
rate in the GCCI arm [2]. The authors suggested that the
incidence of reoperation for bleeding in the GCCI group
was similar to that seen in routine practice, and that
the re-operation rate in the control group was lower
than expected [2].
NICE guidelines 2008 acknowledged the role of GCCI
in ‘Prevention and treatment of surgical site infection’
based on the LOGIP trial [15]. However, it emphasised
the need for evaluation of the long-term effects on
microbial resistance [15].
For the two centres enrolling patients in LOGIP Trial
use of GCCI became a routine practice. As suggested by
NICE guidelines, the authors re-evaluated their technique
with a prospective non randomised study designed for
comparison with the previous control group from the
LOGIP trial [33] (Table 1). The highly significant risk
reduction found in the previous trial at the same institute
raised ethical concerns in randomizing patients again to
control/placebo [33]. They also changed the surgical
technique and use of at least seven single wires for sternal
fixation was emphasized in the protocol of this second
study (compared to 6–8 wires used at Surgeon’s discretion
in the LOGIP Trial) [2,33]. The incidences of both
superficial and deep SWI were less than half of that
in the control group. The incidence of SWI was
slightly lower than that in the treatment group of the
primary LOGIP trial (4.3% SWI with 2.3% deep SWI)
Table 1 A summary of important studies on the use of GCCI (Gentamycin Containing Collagen Implants) in cardiac surgery
Authors Study design, n = Number of
Subjects
Treatment groups Results
Friberg O et al. [2],
2005 LOGIP Trial
Double blind, Randomized, controlled,
two-centre study. Patients undergoing
cardiac surgery through median
sternotomy - including operations in
the ascending aorta.
n = 1950 total patients Wound infection (<2 months
post-operatively):
Treatment Gr (Gr I): Collatamp
between the Sternal edges
(n = 983)
Group I vs Group II 4.3% vs 9.0% (RR 0.47;
p < 0.001)
Control Gr (Gr II): Standard
closure (n = 967)
Early reoperation for bleeding was more
common in the treatment group (4.0% vs
2.3%, p = 0.03).
N = 1950
Standard antibiotic prophylaxis
given to both groups
Need for postoperative antibiotic
treatment: Group I: 11.6% vs Group II:
18.0% (RR 0.64: p < 0.001)
Evaluation: Double blind, ITT
Friberg O et al.
[33], 2009
Prospective study, n = 2326 total patients Wound infection (<60 days postoperative):
Two centre study
(Control Gr from LOGIP Trial)
Treatment Gr (Gr I): n = 1359 Group I vs Gr II 3.7% vs 9.0% p < 0.001
Control Gr (Gr II): n = 967 Surgical revision: Group I vs Group II
1.8% vs 3.9% (p < 0.001)
Standard antibiotic prophylaxis





n = 542 total patients Wound infection (<3 months
post-operatively):
Treatment Gr (Gr I): n = 272
Group I vs Group II 4.0% vs. 5.9% (p = n.s.)
Control Gr (Gr II):
Evaluation: Partially Blinded n = 270 Incidence of mediastinitis: 1.1% vs 1.9%
(P value = NS)
Standard antibiotic prophylaxis
given to both groups. Any patient
staying in hospital for >72 hrs
received IV Vancomycin in addition
to routine IV Cefuroxime.
Schersten et al.
[28], 2007
Prospective Study with historical
controls
n = 2026 total patients Wound infection (mediastinitis): Group I
vs Group II
Treatment Gr (Gr I): n = 1091
Control Gr (Gr II): 0.75% vs 1.9%
n = 935 (p < 0.05)
Standard antibiotic prophylaxis
given to both groups
Leyh et al.
[51], 1999
Observational Study N = 42 Patients of DSWI after
cardiac surgery were treated
with Collatamp with or without
other surgical interventions
No definite conclusion regarding direct
benefit of Collatamp use can be drawn
from this study.(No Control Group) Impact of
GCCI on treatment of DSWI,
to assess side effects of
Gentamycin topical use,
and Gentamycin
High (bactericidal) local levels of
Gentamycin noted in mediastinal fluid





n = 1502 total patients Wound infection (<90 days
post-operatively):
Patients with diabetes
n = 1006 [67%]
Incidence of all types of wound infection
Group I Vs Gr II 8.4% vs 8.7% (p value = n.s.)
Multicentre study Patients with BMI > 30,
n = 1137 [76%]
Patients undergoing cardiac surgery
and at high-risk for sternal wound
infection (diabetes, BMI > 30 or both)
Incidence of DSWI Group I: 1.9% vs. 2.5%
(p value = n.s.)Treatment Gr (Gr I): n = 753
Control Gr (Gr II):
n = 749
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Table 1 A summary of important studies on the use of GCCI (Gentamycin Containing Collagen Implants) in cardiac surgery
(Continued)
Standard antibiotic prophylaxis
given to both groups
Incidence of SSWI Group I: 6.5% vs. 6.1%
(p value = n.s.)
Re-hospitalisation for sternal wound
infection (<90 days post-operatively):





n = 552 total patients
Intervention period
DSWI incidence rate: Intervention period
patients managed with GCCI
n = 175
patients managed with GCCI: 12.6%Diabetic and/or overweight
patients undergoing CABG with
bilateral internal mammary artery
grafts. Intervention period patients
managed without GCCI n = 88
Intervention period patients managed
without GCCI: 6.8%
Retrospective Control Gr,
preintervention era group n = 289
Retrospective Control Gr, preintervention
era group: 13.8%
No statistically significant differences
between three groups.
The group managed with the
sponge had a higher proportion
of gentamicin-resistant micro-organisms.
The end-point was the rate of




Retrospective Case series n = 216 total patients Wound infection: Group I vs Gr II: 0.0%
vs 9.0% (p value = 0.0220).
Treatment Gr (Gr I): n = 108




Patient case series n = 194 total patients Wound infection: Incidence of SSWI
Group I vs Gr II: 2.1% vs 6.2%
(p value = 0.01). Incidence of DSWI
Group I vs Gr II: 2.1% vs 3.1% (p value = n.s)
Patients undergoing cardiac
surgery via sternotomy
Treatment Gr (Gr I): n = 97
Control Gr (Gr II):
n = 97
Standard antibiotic prophylaxis





n = 723 total patients Wound infection (<30 days):
Treatment Gr (GrI) GCCI Gr,
Collagen Implant with
Gentamycin: n = 354
Incidence of SSWI/DSWI
Single-centre study




Comparison of a GCCI versus
a simple Collagen sponge











trials (published between 2005
and 2010) involving 3,994 patients
There is insufficient evidence of the
effectiveness (or otherwise) of GCCI in
preventing SWIs following cardiac surgery.
However, some evidence does exist that
such sponges can reduce the incidence
of deep infections in high risk patients
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Systematic Review and Meta-analysis
of Randomized Trials
Fifteen randomised controlled
trials involving 6979 patients
Use of GCICI was associated with a significant
decrease in SSI with an NNT of 21 p = 0.001;
Post hoc analysis showed that GCCI implants are
effective in reducing SSI in sternotomy wounds.








GCCI reduced the risk of DSWI and need for
surgical revision. No impact on SSWI or all cause
mortality. Most commonly isolated pathogens
were CoNS.
Treatment Group = GCCI Group.
RCT = Randomised Controlled Trial.
NNT = Numbers Needed to Treat.
SSWI = Superficial Sternal Wound Infection.
DSWI = Deep Sternal Wound Infection.
SSI = Surgical Site Infection.
SWI = Sternal Wound Infection.
CoNS = Coagulase Negative Staphylococcus Aureus.
CABG = Coronary Artery Bypass Graft.
BMI = Body Mass Index.
RR = Relative Risk.
OR = Odds Ratio.
CI = Confidence Interval.
Mishra et al. Journal of Cardiothoracic Surgery 2014, 9:122 Page 7 of 11
http://www.cardiothoracicsurgery.org/content/9/1/122probably due to improvement in surgical technique.
However, it is not possible to differentiate the relative
effects of each of the variables (improvement in surgical
technique and impact of GCCI) in improvement of sternal
wound complications [33].
No trend towards less effect over time could be
detected after 7 years of daily use [2,33]. A microbiological
analysis between the two studies after a gap of several
years showed that there had been no change in types of
causative bacteria and no absolute increase in SSIs caused
by aminoglycoside resistant microbes over time [2,33].
The organisms isolated were predominantly CoNS. They
were resistant to both aminoglycosides and methicillin in
approximately 80% of cases. These ‘resistant’ strains may
be susceptible to the extremely high local concentrations
achieved with GCCI [33].
Eklund et al. performed a RCT which did not show
any evidence of beneficial effect of GCCI in prevention
of sternal wound infection [7] (Table 1). However, the
authors emphasised that with the infection rates in their
study (4% study group; 5.9% control group), the sample
size necessary to detect a significant (P < 0.05) RR with a
statistical power of 0.8 would be 1275 patients in each
group. The authors acknowledged that the study was too
small to draw any firm conclusions (total 542 patients
with 272 and 270 patients in each group).
Schersten et al. reported that after adding GCCI to
their standard treatment protocol in a consecutive and
unselected series of 1091 patients, they noticed a significant
drop in the rate of mediastinitis [28] (Table 1). However, in
this series of patients they made a significant change in
their sternal closure technique (emphasis on more than 7
sternal wires for all patients) and it was difficult to discernthe impact of GCCI alone in bringing down the rate of
mediastinitis [28].
Leyh et al. treated mediastinitis with sternum refixation
and gentamicin-collagen sponge successfully in 42 patients
[51] (Table 1). The study was designed for effectiveness of
measures to treat DSWI and not for prevention. Use of
Collatamp resulted in high mediastinal fluid level of
Gentamicin which will be bactericidal for even Gentamicin
resistant strains (15% organisms were Gentamicin resistant
in this study) [51]. However, as all patients were treated
with multiple interventions, no definite conclusion can be
drawn from this study regarding direct beneficial effect of
GCCI use in treatment of DSWI [51].
Bennett-Guerrero conducted a multicenter RCT of
1502 patients in US for patients undergoing cardiac
surgery and at high-risk for sternal wound infection
(diabetes, BMI > 30 or both) [67] (Table 1). No significant
difference was noted in the rates of SSWI or DSWI or
rehospitalisation rate for wound infection up to 90 days
after surgery [67]. Similarly, Birgand et al. conducted
a quasi-experimental single-centre prospective study in
diabetic and/or overweight patients undergoing coronary-
artery bypass surgery with bilateral internal mammary
artery grafts [68] (Table 1). They found no evidence of
efficacy of GCCI [68]. Interestingly in both these studies
GCCI were soaked in saline prior to use [67,68].
Corn T et al., Raja et al. and Friberg O et al. challenged
the findings of these studies which were in contrast to the
findings of several other contemporary studies [68-70].
The study protocol and the training video of the study
by Bennett-Guerrero et al. describes dipping GCCI
for 1–2 sec in saline prior to use [69-71]. The GCCI used
in this trial is marketed by EUSA Pharma (Europe) which
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should be used dry [66,69]. Gentamicin sulfate is highly
soluble in aqueous solutions and dipping it in saline prior
to use alters the release characteristics of Gentamicin
decreasing its efficacy [66,69].
Lovering et al. conducted a study evaluating the impact
of soaking gentamicin- containing collagen implants on
potential antimicrobial efficacy of GCCI [72]. The study
showed that even a short period of dipping of gentamicin-
collagen sponge, before insertion into the patient, results
in a significant loss of gentamicin [72]. The mean loss of
Gentamicin was 6.7% at 2 s, increasing to 40.5% at 1 min
and essentially total loss by 6 h of immersion [72]. This
study provides clinching evidence that even a short period
of dipping of Collatamp implants, before insertion into
the patient results in a significant loss of gentamicin which
may be of clinical significance [72].
In a retrospective review Cohen and colleagues
compared a group of 108 patients who had received
GCCI to a group of matched contemporary controls
on a 1:1 basis [73] (Table 1). There was a significant
difference in the incidence of post-operative SSI between
the two groups (0% GCCI vs. 9% standard treatment;
p value 0.022). Raja and colleagues conducted a propensity
score analysis and compared the adjunctive use of GCCI
in patients deemed at high risk of developing SSI to a
group of matched controls [50] (Table 1). This study
demonstrated a significant benefit of GCCI, which
reduced the rate of superficial wound infection by 66%
compared to standard treatment alone (2.1% GCCI vs.
6.2% standard treatment; p value 0.01) [50]. Although the
patients in the GCCI group also had a lower rate of deep
wound infection compared to the control group, this
difference did not reach statistical significance [50].
Most of these studies compared GCCI versus routine
antibiotic prophylaxis and suffered from a limitation as
there were no control arms for Collagen sponge without
Gentamycin. Schimmer et al. addressed this issue with a
double blind RCT Comparison of a GCCI versus a simple
Collagen sponge [74] (Table 1). The two types of sponges
were implanted retrosternally in dry condition. This study
has shown a significant reduction in DSWI and SSWI in
patients undergoing median sternotomy for cardiac
surgery with routinely application of a GCCI. Numbers
needed to treat (NNT) for all sternal wound infections
and deep sternal wound infections were 26 and 33,
respectively [74].
Multiple randomized controlled trials (RCTs) produced
conflicting results [74]. Creanor et al. performed a meta
analysis of three randomised controlled trials (published
between 2005 and 2010) involving 3,994 participants [12]
(Table 1). Using random effects models, odds ratios (OR)
and corresponding 95% confidence intervals (CI) were
calculated for all SWIs and deep SWIs. There wasinsufficient evidence of the effectiveness (or otherwise) of
gentamicin impregnated sponges in preventing SWIs
following cardiac surgery. However, some evidence does
exist that such sponges can reduce the incidence of deep
infections in high risk patients. Chang et al. therefore
conducted a systematic review and meta-analysis of all
relevant RCTs [75] (Table 1). Fifteen RCTs encompassing
a total of 6979 patients were included. The included
studies were of moderate to high quality. Gentamicin-
collagen implants significantly reduced SSI [OR = 0.51;
95% CI: 0.33–0.77; P = 0.001 [75].
Mavros et al. performed a meta-analysis of randomized
controlled trials [76] (Table 1). Four RCTs were considered
of high quality (score of 3 or more according to modified
Jadad criteria) and were included in the study (4672
patients). GCCI reduced risk of DSWI (risk ratio,
0.62; 95% confidence interval, 0.39-0.97). However, no
benefit was demonstrated regarding superficial sternal
wound infections and all-cause mortality [76]. Pooled data
from 2 randomized controlled trials (3410 patients),
showed that use of GCCI also reduced the need for surgi-
cal revision of sternal wounds (risk ratio, 0.59; 95% confi-
dence interval, 0.41-0.86). The most commonly isolated
pathogens were coagulase-negative Staphylococcus spp
(43%) and Staphylococcus aureus (28%) [76]. The
authors concluded that there is large statistical heterogen-
eity among the existing trials and emphasised the need for
additional large, high-quality randomized controlled
trials [76].
Popescu et al. did a retrospective audit of 2238 patients
where Collatamp was used in only 122 patients (5%) [77].
The rate of sternal wound infection in non-Collatamp
group was 3% while it was 5% in Collatamp group [77].
The length of stay in hospital was shorter in Collatamp
patients. No gentamicin sensitivity was recorded within
the Collatamp group. Because of the small numbers and
retrospective nature of the study no definite conclusion
could be drawn [77].
It should be noted that in cardiothoracic surgery,
where the infection rate is low, it is difficult to perform
studies with appropriate statistical power. Eklund et al.
highlighted that with the infection rates in their study
(4% study group; 5.9% control group), the sample size
necessary to detect a significant (P < 0.05) RR with a
statistical power of 0.8 would be 1275 patients in each
group [7]. As a result several studies are small, inadequately
powered and it’s difficult to draw firm conclusions from
such studies.
Conclusion
Safety and efficacy of GCCI (Collatamp) has been
debated and tested in several recent studies with
conflicting results. Several recent studies have sup-
ported their clinical effectiveness. They should be
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to use.
Based on the evidence presented in this manuscript, it is
recommended GCCI (Collatamp) can be a cost effective
adjunct for prevention of sternal wound infection. They
can also be used for treatment of DSWI.
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